Laventair Ellipta: Uses, Dosage & Side Effects

What Is Laventair Ellipta and What Is It Used For?

Laventair Ellipta is a fixed-dose combination of two long-acting bronchodilators delivered via the Ellipta dry powder inhaler. Each pre-dispensed dose contains umeclidinium bromide equivalent to 55 micrograms of umeclidinium and vilanterol trifenatate equivalent to 22 micrograms of vilanterol. These two active substances belong to different pharmacological classes and work through distinct and complementary mechanisms to relax the smooth muscle lining the airways in the lungs, thereby improving airflow in patients with chronic obstructive pulmonary disease (COPD).

Umeclidinium is a long-acting muscarinic antagonist (LAMA), also known as a long-acting anticholinergic. It works by blocking the action of acetylcholine at muscarinic M3 receptors on airway smooth muscle cells. In COPD, the parasympathetic nervous system contributes to bronchoconstriction through the release of acetylcholine, which binds to M3 receptors and causes the airway smooth muscle to contract. By competitively inhibiting this interaction, umeclidinium prevents acetylcholine-induced bronchoconstriction and promotes sustained relaxation of the airway smooth muscle. Umeclidinium has a high affinity for M3 receptors and dissociates slowly, contributing to its long duration of action that supports once-daily dosing.

Vilanterol is a long-acting beta2-adrenergic agonist (LABA). It works by stimulating beta2-adrenergic receptors on airway smooth muscle cells, which activates adenylyl cyclase and increases intracellular levels of cyclic adenosine monophosphate (cAMP). Elevated cAMP levels lead to activation of protein kinase A, which phosphorylates several intracellular targets resulting in relaxation of airway smooth muscle, inhibition of mediator release from mast cells, and improved mucociliary clearance. Vilanterol has a rapid onset of action (within minutes of inhalation) and a long duration of action exceeding 24 hours, providing sustained bronchodilation throughout the dosing interval.

The rationale for combining a LAMA and a LABA in a single inhaler is well-established in respiratory medicine and supported by robust evidence from clinical trials and international guidelines. Because umeclidinium and vilanterol act through different and complementary signaling pathways, their combined bronchodilatory effect is additive. This means that dual bronchodilation with Laventair Ellipta produces greater improvements in lung function (as measured by forced expiratory volume in one second, or FEV1) than either component used alone, without a proportional increase in side effects. The 2024 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend LAMA/LABA combination therapy for COPD patients with persistent breathlessness despite monotherapy, as well as for those with a high symptom burden or a history of exacerbations.

COPD is a progressive lung disease characterized by persistent airflow limitation that is usually associated with a chronic inflammatory response in the airways and lungs to noxious particles or gases, most commonly cigarette smoke. It encompasses chronic bronchitis (inflammation and narrowing of the bronchial tubes with excess mucus production) and emphysema (destruction of the alveolar walls resulting in air trapping and reduced gas exchange). COPD affects an estimated 380 million people worldwide according to the World Health Organization (WHO) and is the third leading cause of death globally. Symptoms include chronic breathlessness (dyspnea), persistent cough, sputum production, wheezing, and reduced exercise tolerance.

The pivotal clinical trials supporting the efficacy of Laventair Ellipta include study DB2113361 and study DB2113373, which were large, randomized, double-blind, placebo-controlled trials in patients with moderate to severe COPD. In these studies, once-daily inhalation of umeclidinium/vilanterol 55/22 mcg demonstrated statistically significant and clinically meaningful improvements in trough FEV1 (measured 24 hours after the previous dose) compared with placebo, umeclidinium alone, and vilanterol alone. The combination also showed improvements in patient-reported outcomes including the Transition Dyspnea Index (TDI) score and the St George's Respiratory Questionnaire (SGRQ) total score, indicating better symptom control and quality of life. Reductions in rescue albuterol (salbutamol) use further confirmed the clinical benefit.

What Should You Know Before Taking Laventair Ellipta?

Contraindications

Laventair Ellipta is contraindicated in patients with a known severe hypersensitivity to umeclidinium, vilanterol, or any of the excipients (including lactose monohydrate and magnesium stearate). Hypersensitivity reactions including anaphylaxis, angioedema, and rash have been reported with Laventair Ellipta and its individual components. If a hypersensitivity reaction occurs, the medication should be discontinued immediately and alternative treatment initiated. Patients with severe milk protein allergy should not use this product, as the lactose excipient contains milk proteins.

Laventair Ellipta is not indicated for the treatment of asthma. The safety and efficacy of Laventair Ellipta in patients with asthma have not been established. The LABA component (vilanterol) carries a class warning: data from large placebo-controlled studies (including the SMART trial with salmeterol) showed that LABAs may increase the risk of asthma-related hospitalization and death when used without an inhaled corticosteroid (ICS). Since Laventair Ellipta does not contain an ICS, it should never be prescribed for asthma.

Warnings and Precautions

Laventair Ellipta should not be used as a rescue medication for the treatment of acute episodes of bronchospasm. In such situations, a short-acting inhaled beta2-agonist (such as salbutamol/albuterol) should be used. Increasing use of short-acting bronchodilators to relieve symptoms may indicate deterioration of disease control and the need for reassessment of COPD management.

Paradoxical bronchospasm, a condition in which the inhaler causes sudden worsening of wheezing and shortness of breath immediately after use, has been reported with inhaled medications including Laventair Ellipta. If paradoxical bronchospasm occurs, treatment should be stopped immediately, the patient should be assessed, and alternative therapy initiated if necessary. This is a potentially life-threatening adverse event that requires prompt medical attention.

Cardiovascular effects may occur with Laventair Ellipta, as with all medicinal products containing sympathomimetic amines (such as vilanterol). These include increases in heart rate, blood pressure, and electrocardiographic changes (including QTc prolongation and ST-segment depression). In patients with coronary artery disease, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or any form of cardiovascular disease, Laventair Ellipta should be used with caution and patients should be monitored for cardiovascular effects. In the pivotal clinical trials, clinically significant cardiovascular effects were uncommon at the recommended dose.

Caution is also advised in patients with the following conditions: convulsive disorders (seizure history), thyrotoxicosis (overactive thyroid), narrow-angle glaucoma, urinary retention (particularly in patients with prostatic hyperplasia or bladder-neck obstruction), severe hepatic impairment, and diabetes mellitus. Beta2-agonists such as vilanterol may cause transient hyperglycemia and hypokalemia, which may be particularly relevant in patients with diabetes or those taking medications that lower serum potassium.

Anticholinergic effects are inherent to the LAMA component (umeclidinium) and may include dry mouth, constipation, urinary retention, and increased intraocular pressure. Patients with narrow-angle glaucoma should be specifically warned about the risk of acute angle-closure glaucoma and advised to seek immediate medical attention if they develop eye pain, blurred vision, visual halos, or colored images in association with red eyes.

Pregnancy and Breastfeeding

There are limited clinical data on the use of Laventair Ellipta during pregnancy. Animal reproductive studies with umeclidinium and vilanterol individually did not show evidence of teratogenicity at clinically relevant exposures, but beta2-agonists may interfere with uterine contractility during labor. Laventair Ellipta should be used during pregnancy only if the expected benefit to the mother justifies the potential risk to the fetus. Women who are pregnant or planning to become pregnant should discuss the risks and benefits with their healthcare provider.

It is unknown whether umeclidinium or vilanterol and their metabolites are excreted in human breast milk. A risk to the breastfed infant cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue Laventair Ellipta therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. Healthcare providers should weigh these considerations on a case-by-case basis.

How Does Laventair Ellipta Interact with Other Drugs?

While clinically significant drug interactions with Laventair Ellipta are uncommon at recommended doses, several pharmacological interactions should be considered. Umeclidinium is primarily metabolized by cytochrome P450 2D6 (CYP2D6), while vilanterol is primarily metabolized by CYP3A4. Understanding these metabolic pathways is important for anticipating potential interactions with other medications.

Major Interactions

Non-selective beta-blockers (e.g., propranolol, carvedilol, nadolol) may diminish or abolish the bronchodilatory effect of vilanterol (the LABA component). Beta-blockers and beta2-agonists have opposing pharmacological mechanisms, and concurrent use can lead to severe bronchospasm in COPD patients. If beta-blocker therapy is required, cardioselective beta-blockers (e.g., bisoprolol, metoprolol) should be considered, and the patient should be monitored closely. Even cardioselective beta-blockers should be used with caution.

Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, cobicistat, clarithromycin) may increase systemic exposure to vilanterol. In a pharmacokinetic interaction study, co-administration with ketoconazole increased vilanterol systemic exposure (AUC) by approximately 65% and maximum concentration (Cmax) by 22%. This increased exposure may lead to increased cardiovascular adverse effects such as heart rate elevation, QTc prolongation, and cardiac arrhythmias. Caution is advised when Laventair Ellipta is administered with strong CYP3A4 inhibitors.

Other long-acting anticholinergics or LABAs should not be used concurrently with Laventair Ellipta. Co-administration of other muscarinic antagonists (e.g., tiotropium, glycopyrronium) or other LABAs (e.g., formoterol, salmeterol, indacaterol) with Laventair Ellipta has not been studied but may result in additive anticholinergic or sympathomimetic effects and an increased risk of adverse reactions.

Minor Interactions

QT-prolonging medications (e.g., certain antiarrhythmics, macrolide antibiotics, fluoroquinolones, antipsychotics, tricyclic antidepressants) may have an additive effect with vilanterol on QTc interval prolongation. While vilanterol at therapeutic doses has not shown clinically significant QTc effects, patients receiving concomitant QT-prolonging therapy should be monitored appropriately.

Potassium-depleting agents such as thiazide diuretics, loop diuretics (e.g., furosemide), and corticosteroids may potentiate hypokalemia caused by beta2-agonists. Low serum potassium levels may increase the risk of cardiac arrhythmias. Monitor serum potassium levels in patients receiving concurrent therapy, particularly in acute or unstable COPD.

Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants: Vilanterol, like other beta2-agonists, should be administered with caution in patients taking MAOIs or tricyclic antidepressants, as the cardiovascular effects of beta2-agonists may be potentiated. The mechanism involves reduced metabolism and potentiated sympathomimetic effects.

What Is the Correct Dosage of Laventair Ellipta?

Adults

The recommended and maximum dose of Laventair Ellipta in adults is one inhalation (55 micrograms umeclidinium / 22 micrograms vilanterol) once daily. The inhaler delivers a fixed dose, so there is no need to adjust the number of inhalations. Patients should be instructed to take their daily dose at the same time each day to maintain consistent bronchodilator coverage over the 24-hour dosing interval. If a dose is taken at an inconsistent time, the next dose should be taken at the usual time the following day.

Onset of bronchodilatory effect occurs within minutes of inhalation, with vilanterol providing rapid onset while umeclidinium contributes to sustained duration. Peak improvement in lung function is typically observed within 2 to 3 hours after inhalation, and clinically meaningful bronchodilation is maintained over the full 24-hour period. Patients should understand that Laventair Ellipta is a maintenance treatment and should be used regularly every day, even when symptoms appear to improve. It should not be stopped without consulting a healthcare professional.

Children and Adolescents

Laventair Ellipta is not indicated for use in children and adolescents under 18 years of age. COPD does not normally occur in this age group. There are no data available on the safety and efficacy of umeclidinium/vilanterol in patients under 18 years, and no dose recommendation can be made for this population.

Elderly Patients

No dose adjustment is required for elderly patients (aged 65 years and over). Clinical trials with Laventair Ellipta included a significant proportion of patients aged 65 years and over. In the pivotal efficacy and safety studies, approximately 45% of enrolled patients were aged 65 years or older, and approximately 13% were aged 75 or older. No overall differences in safety or effectiveness were observed between these patients and younger adult patients in clinical trials. Population pharmacokinetic analyses showed no clinically significant effect of age on the pharmacokinetics of umeclidinium or vilanterol. The Ellipta device is designed with simplicity in mind, requiring minimal inspiratory effort compared to other dry powder inhalers, which is an advantage for elderly patients who may have reduced inspiratory flow rates.

Renal and Hepatic Impairment

No dose adjustment is required for patients with mild to moderate renal or hepatic impairment. Umeclidinium and vilanterol are primarily eliminated through hepatic metabolism, with only a small fraction excreted unchanged in the urine. In a dedicated hepatic impairment study, subjects with moderate hepatic impairment (Child-Pugh class B) showed no clinically relevant changes in umeclidinium or vilanterol pharmacokinetics. Laventair Ellipta has not been studied in patients with severe hepatic impairment (Child-Pugh class C), and caution is advised in this population. Similarly, no dedicated renal impairment study has been conducted, but given the minimal renal clearance of both active substances, no dose adjustment is expected to be necessary in patients with renal impairment.

Missed Dose

If a dose is missed, the patient should take the next dose at the usual time on the following day. Patients should not take a double dose to make up for a missed one. If a dose is missed, the patient may notice increased breathlessness; they should use their short-acting rescue inhaler (e.g., salbutamol/albuterol) as needed for symptom relief until the next scheduled dose of Laventair Ellipta.

Overdose

There is no specific antidote for overdose with Laventair Ellipta. In case of overdose, the patient should receive supportive care and monitoring as appropriate. Signs and symptoms of overdose would be expected to relate to exaggerated pharmacological effects of the individual components: for umeclidinium, this may include anticholinergic effects such as dry mouth, visual disturbances, tachycardia, and urinary retention; for vilanterol, this may include tremor, headache, palpitations, tachycardia, hypokalemia, hyperglycemia, and cardiac arrhythmias. Beta-adrenergic blocking agents may be considered for treatment of beta2-agonist overdose effects, but should be used with extreme caution in COPD patients as they may provoke bronchospasm. Cardiac monitoring is recommended in cases of significant overdose.

What Are the Side Effects of Laventair Ellipta?

Like all medicines, Laventair Ellipta can cause side effects, although not everybody gets them. The overall safety profile of Laventair Ellipta has been established in multiple clinical trials enrolling thousands of COPD patients and is consistent with the known pharmacological effects of its LAMA and LABA components. Most side effects observed in clinical trials were mild to moderate in severity and did not require discontinuation of treatment.

The side effects reported during clinical development and post-marketing surveillance are categorized below according to their frequency using the standard classification: very common (affects more than 1 in 10 patients), common (affects 1 in 10 to 1 in 100 patients), uncommon (affects 1 in 100 to 1 in 1,000 patients), rare (affects fewer than 1 in 1,000 patients), and not known (frequency cannot be estimated from available data).

In clinical trials, the overall incidence of adverse events was similar between Laventair Ellipta and placebo groups. The most frequently reported adverse events leading to study withdrawal were COPD exacerbation, pneumonia, and dyspnea. The cardiovascular safety of Laventair Ellipta was extensively studied, including Holter monitoring and detailed ECG analyses, which showed no clinically meaningful difference in cardiac arrhythmias or QTc prolongation between Laventair Ellipta and placebo at the recommended dose.

Particular attention should be paid to certain class effects. The anticholinergic effects of umeclidinium (dry mouth, constipation, urinary retention, and increased intraocular pressure) tend to be mild but may be more troublesome in elderly patients or those with pre-existing conditions such as prostatic hyperplasia or narrow-angle glaucoma. The beta2-agonist effects of vilanterol (tremor, palpitations, tachycardia, and hypokalemia) are dose-related and were infrequent at the therapeutic dose of 22 mcg.

How Should You Store Laventair Ellipta?

Proper storage of Laventair Ellipta is important to ensure that the inhalation powder remains stable, effective, and safe to use throughout the life of the inhaler. The dry powder formulation is sensitive to moisture, which is why the Ellipta inhaler is supplied in a sealed moisture-protective aluminum tray containing a desiccant sachet.

Before opening the tray: Store at temperatures below 30°C (86°F). Do not freeze. Do not refrigerate. Keep in a dry place. The unopened tray protects the inhaler from moisture until it is ready for first use.

After opening the tray: Once the foil tray is opened, the inhaler should be used within 6 weeks. Write the date the tray was opened in the space provided on the inhaler label to help track this period. The desiccant sachet should be discarded and must not be eaten or inhaled. Keep the cover of the Ellipta inhaler closed when not in use to protect the mouthpiece and prevent inadvertent release of a dose.

Dose counter: The Ellipta inhaler has a built-in dose counter that shows how many doses remain. When the counter reaches 0, the inhaler is empty and should be discarded. Each Laventair Ellipta inhaler contains 30 doses (a one-month supply when used once daily). The inhaler should be discarded 6 weeks after the tray is opened or when the dose counter reads 0, whichever comes first.

Keep Laventair Ellipta and all medicines out of the reach and sight of children. Do not use the medicine after the expiry date stated on the carton and the inhaler label after "EXP." The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste; ask your pharmacist how to dispose of medicines you no longer use to help protect the environment.

What Does Laventair Ellipta Contain?

Laventair Ellipta contains two active substances formulated as a dry powder for inhalation within the Ellipta inhaler device. The Ellipta inhaler contains two separate foil blister strips: one strip contains umeclidinium bromide and the other contains vilanterol trifenatate. When the cover is opened, both strips are advanced simultaneously to expose one blister from each strip, ensuring accurate co-delivery of both active substances with each inhalation.

Active substances:

• Umeclidinium bromide – Each delivered dose (the dose that leaves the mouthpiece) contains 55 micrograms of umeclidinium (equivalent to 65 micrograms of umeclidinium bromide per blister). Umeclidinium bromide is a white crystalline powder with the molecular formula C₂₉H₃₄NO₂·Br and a molecular weight of 508.49 g/mol.
• Vilanterol trifenatate – Each delivered dose contains 22 micrograms of vilanterol (equivalent to 25 micrograms of vilanterol trifenatate per blister). Vilanterol trifenatate is a white crystalline powder with the molecular formula C₂₄H₃₃Cl₂NO₅·C₁₈H₁₅O₄P and a molecular weight of 774.77 g/mol.

Excipients (inactive ingredients):

• Lactose monohydrate – Used as a carrier for the active ingredients in the dry powder formulation. Important: Lactose monohydrate contains trace amounts of milk proteins. Patients with severe milk protein allergy (not lactose intolerance) should not use Laventair Ellipta.
• Magnesium stearate – Used as a lubricant in the powder formulation to ensure consistent powder flow and dose uniformity.

The Ellipta inhaler itself is made from light grey polycarbonate, polyethylene (PE), polypropylene (PP), polyoxymethylene (POM), and stainless steel components. It is a single-use, non-reloadable device designed for disposal after the dose counter reaches zero or 6 weeks after opening, whichever comes first.